Orleans Capital Management Corp Bristol Myers Squibb CO Transaction History

Orleans Capital Management Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $786,442 - $938,442	-16,222 Reduced 52.43%	14,721 $755,000
Q3 2023 Nov 15, 2023	SELL	$57.89 - $64.73 $84,808 - $94,829	-1,465 Reduced 4.52%	30,943 $1.8 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $31,217 - $34,662	-490 Reduced 1.49%	32,408 $2.07 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $3,285 - $3,726	50 Added 0.15%	32,898 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $69,507 - $82,306	1,015 Added 3.19%	32,848 $2.36 Million
Q3 2022 Nov 15, 2022	SELL	$0.13 - $76.84 $19 - $11,526	-150 Reduced 0.47%	31,833 $2.26 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $67,899 - $74,781	935 Added 3.01%	31,983 $2.46 Million
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $642,466 - $770,374	10,450 Added 50.73%	31,048 $2.27 Million
Q4 2021 Feb 15, 2022	SELL	$53.63 - $62.52 $466,151 - $543,423	-8,692 Reduced 29.68%	20,598 $1.28 Million
Q3 2021 Nov 18, 2021	SELL	$59.17 - $69.31 $9,763 - $11,436	-165 Reduced 0.56%	29,290 $1.73 Million
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $24,764 - $26,968	-400 Reduced 1.34%	29,455 $1.97 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $356,040 - $400,439	6,000 Added 25.15%	29,855 $1.89 Million
Q4 2020 Feb 19, 2021	SELL	$57.74 - $65.43 $559,500 - $634,016	-9,690 Reduced 28.89%	23,855 $1.48 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $8,614 - $9,546	-150 Reduced 0.45%	33,545 $2.02 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $1.85 Million - $2.16 Million	33,695 New	33,695 $1.98 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Orleans Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Orleans Capital Management Corp with notifications on news.